As aberrant NIK activity driving constitutive activation of both canonical and non-canonical NF-κB signaling constitutes a common consequence of most of the genetic aberrations found in a large subset of multiple myeloma and Hodgkin lymphoma patients, pharmacological NIK inhibition represents an attractive therapeutic strategy for the treatment of these tumor entities. Here, NFKB1 is linked to plasma cell myeloma.